Light Science Technologies

Result of Fundraising and WRAP Retail Offer

the Company's announcements of 4 and 5 April 2023 the issue of the Conditional Placing Shares, Subscription Shares and WRAP Retail Offer Shares are subject to the approval of the Company's shareholders at a General Meeting, which has been convened for 21 April 2023 and formal notice of which was sent to shareholders on 5 April 2023.   Admission and total voting rights Application has been made for the 78,250,000 Conditional Placing Shares, 35,500,000 Subscription Shares and 15,605,500 WRAP Retail Offer Shares to be admitted to trading on AIM which is expected to take effect and dealings …

WRAP Retail Offer for up to £0.50 million

THIS ANNOUNCEMENT.   THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY WINTERFLOOD SECURITIES LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 141455).   05 April 2023   Light Science Technologies Holdings plc (" Light Science " or the " Company ")   WRAP Retail Offer for up to £0.50 million   Light Science is pleased to announce a retail offer via the Winterflood Retail Access Platform (" WRAP ") to raise up to £0.50 million gr…

Proposed £1.50 million Placing and Subscription

the Company, has agreed to subscribe for 15,000,000 Subscription Shares.   The Placing has been conducted by Oberon Investments Limited ("Oberon Capital"). Of the 107,750,000 Placing Shares, 29 ,500,000 Placing Shares have been placed with a single investor utilising the Company's existing authority to allot shares for cash on a non-pre-emptive basis (the "Firm Placing Shares"). The Firm Placing Shares are expected to be admitted to trading on AIM at 8.00 a.m. on 5 April 2023 ("First Admission").   The issue of the balance of 78,250,000 Placing Shares (the "Conditional Placing Shares")…

Weekly highlights including 'B HODL PLC announced the purchase of Bitcoin funded by the Company's first At-the-Market equity offering and Capital Deployment Programme.'

Delighted to give existing investors the opportunity to participate in the fundraise. Retail offer to raise up to ~£2 million via BookBuild platform.

Delighted to have advised Andrew Webb et al on this latest raise. 2026 will be a very exciting year for CRISM Therapeutics as it kicks off Phase 2 trial. Retail offer now live on BookBuild.

Broker personnel promoting active retail offer on personal LinkedIn

SP Angel delighted to act as NOMAD and sole broker to CRISM Therapeutics on its £1.0 million fundraising.

Savannah Resources' own LinkedIn page and Proactive Investors posted about multiple fundraises: a £9.2m oversubscribed placing and subscription (scaled back from higher demand), a £6.5m fundraise at market price made available to private investors via PrimaryBid (July 2023), a £6.1m placing and subscription, and a further £1m placing to a major shareholder. The retail offer component via PrimaryBid was highlighted as providing retail shareholder access. CEO also discussed Barroso lithium project funding on Proactive.

LinkedIn posts from company page: linkedin.com/company/savannah-resources-plc. Proactive post: linkedin.com/posts/proactive-investors_savannah-resources-ceo-outlines-way-forward-activity-7348705237223833601. Pattern of repeat raises with PrimaryBid retail component is consistent with the 'repeat raises' concern.

Faron Pharmaceuticals' LinkedIn page and Proactive Investors referenced a €7.1m share offering (late October 2024) and a larger February 2025 accelerated bookbuild placing that was 1.8x oversubscribed, raising EUR 12m (upsized from EUR 10m target). 6,976,744 shares issued at EUR 1.72. The placing was explicitly designed to address financial covenant requirements. Company acknowledged that without the raise, it could not meet minimum cash covenants agreed with lender IPF.

Faron LinkedIn: linkedin.com/company/faron. Post about new CFO: fi.linkedin.com/posts/faron_faron-pharmaceuticals-moving-into-next-phase-activity-7049404979370958848. The covenant breach risk is well-documented in RNS but LinkedIn posts from the company itself do not highlight this risk prominently.

2026 outlook post highlighting clinical milestones: POLB 001 TOPICAL trial interim data expected summer 2026, Oral GLP-1 PoC topline data expected H1 2026. States company is 'funded through this catalyst-rich period, with a cash runway extending into 2027'.

No direct fundraise announcement found on LinkedIn for Poolbeg. This post emphasises cash runway to 2027. No BookBuild or retail targeting language found in any Poolbeg LinkedIn posts. A separate profile (Michael Fleming) mentioned participating in a Poolbeg share placing with £100k investment, but post not directly accessible. URL: https://www.linkedin.com/posts/poolbeg-pharma_polb-catalystrich-aim-activity-7415289997668360192-LCu-

StockBox interview with CEO Nick Tulloch. Highlights: "First helium production at the Rost Well targeted for Q3 2025", strong flow rates, plans for AIM listing. Tulloch claimed Mendell is "the only one extracting helium and selling it by the day" among London-listed helium companies, projected "250 MCF a day" production generating "significant revenue fairly quickly."

CEO making forward-looking production and revenue projections without any caveat language or risk warnings. Uniqueness claims ("only one extracting helium") unsubstantiated.